QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Polatuzumab Vedotin Classification, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Polatuzumab Vedotin: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which operational control would best improve the quality of case assessment for polatuzumab-containing regimens?

Use a generic adverse-event form without treatment-line or regimen fields Use targeted questionnaires that capture full regimen, treatment line, baseline neuropathy, cytopenias, infection risk, TLS factors and neurological work-up when relevant Collect only the suspected product's dose and omit concomitant treatment Limit follow-up to events occurring on the day of infusion

Question 2 of 10 Why is delayed follow-up important after the last polatuzumab dose in a serious infection case?

All treatment-related effects end immediately when plasma drug concentrations decline Marrow and immune recovery may lag behind exposure, allowing treatment-related vulnerability to persist after dosing Delayed events cannot be treatment-related and should be excluded from analysis Only infusion reactions can occur after the final dose

Question 3 of 10 Why is CD79b a suitable target for an antibody-drug conjugate in B-cell lymphoma?

It is expressed only on malignant plasma cells and is absent from mature B cells It is part of the B-cell receptor complex and is expressed on many mature B cells and B-cell malignancies It is a circulating enzyme that cleaves the ADC linker in plasma It is a tumour-specific antigen found exclusively in diffuse large B-cell lymphoma

Question 4 of 10 Which record would best demonstrate that a pharmacovigilance system can assess a suspected PML case appropriately?

A case record containing only the term 'neurological disorder' Documentation of neurological evolution, MRI, CSF JC-virus testing, immune status, prior therapies and alternative diagnoses A product batch number without any clinical information A single negative laboratory result with no follow-up

Question 5 of 10 A patient receives several infused biological products on the same day and develops dyspnoea and hypotension. What is the most important immediate attribution information?

The patient's lymphoma subtype alone Which product was infusing, the sequence of administrations and the exact onset relative to each infusion The patient's prior platelet count only Whether the patient had previously experienced neuropathy

Question 6 of 10 Why should a neuropathy case not be attributed solely from the date of onset?

Neuropathy is unrelated to cumulative exposure and always appears immediately after infusion The patient may have pre-existing neuropathy or exposure to other neurotoxic agents, and symptoms may evolve over time Neuropathy can only be assessed using laboratory tests rather than clinical information The onset date is relevant only for infusion reactions and not for neurological events

Question 7 of 10 A spontaneous report describes 'polatuzumab' but does not specify the full product identity. What is the principal pharmacovigilance concern?

The report is automatically invalid because shortened names are never usable The identity may be ambiguous, potentially obscuring that the product is a payload-bearing ADC and weakening product-level analysis Only the patient's age can be affected by incomplete product naming The shortened name is preferable because it prevents confusion with the linker

Question 8 of 10 What is the key pharmacovigilance implication of the expansion from relapsed/refractory DLBCL use to previously untreated DLBCL use?

All patients can be analysed as one homogeneous safety population Aggregate analyses should preserve treatment-line differences because prior therapy, marrow reserve, disease status and treatment intent affect background risk Only first-line cases are relevant for safety signal detection Treatment line matters only for efficacy and has no relevance to adverse-event interpretation

Question 9 of 10 Which description best captures the pharmacological architecture of polatuzumab vedotin?

An unconjugated anti-CD20 antibody that relies mainly on complement-mediated B-cell depletion A CD79b-directed antibody-drug conjugate that delivers MMAE after internalisation and intracellular processing A small-molecule kinase inhibitor that blocks B-cell receptor signalling in the cytoplasm A cytokine therapy that activates immune-mediated destruction of lymphoma cells

Question 10 of 10 A patient receiving polatuzumab with R-CHP develops severe neutropenia. What is the most appropriate pharmacovigilance interpretation?

Polatuzumab must be the sole cause because it is the named product of interest The event should be considered in the context of polatuzumab, cytotoxic partners, disease, prior therapy and marrow reserve Neutropenia is necessarily caused by rituximab and excludes contribution from chemotherapy The event cannot be assessed because combination regimens make causality impossible

Professional Knowledge Assessment: Polatuzumab Vedotin Classification, Mechanism, Safety and Pharmacovigilance

Cookie Settings